JPRN-UMIN000005612已完成4 期
Genetic-Disease Outcome Consortium-Aliskiren Study - G-DOC-ALIS Study
GENOMIC DISEASE OUTCOME CONSORTIUM (G-DOC) STUDY INVESTIGATORS0 个研究点目标入组 100 人开始时间: 2011年5月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) HbA1c>9% 2) Serum Kalium>5.2mEq/l 3) eGFR<30ml/min/1.73m2 4) Other trial drugs within 30 days 5) Treated with aldosterone blockers or ARB 6) Acute Heart Failure 7) Chronic liver disease, malignant hypertension, stroke, acute coronary syndrome, acute myocardial infarction, PCI or angioplasty within 3 months 8) Pregnancy
研究者
相似试验
已完成
不适用
Association study of genome for common disease, especially circulatory diseases, renal disases and hypertension.JPRN-UMIN000013004Yokohama City University Graduate School of Medicine1,000
未知
不适用
Genome-wide case-control association study to identify susceptibility gene to diabetic nephropathy using single nucleotide polymorphisms.Diabetic nephropathyJPRN-C000000272RIKE2,000
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
已完成
不适用
Prevalence of Non Communicable Disease study- Indian rural populatioCTRI/2018/08/015376Kovai Medical Center and Hospital865